Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Net Margin (2020 - 2026)

Opus Genetics has reported Net Margin over the past 8 years, most recently at 3038.25% for Q1 2026.

  • Quarterly Net Margin fell 285074.0% to 3038.25% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 892.36% through Mar 2026, down 46295.0% year-over-year, with the annual reading at 349.33% for FY2025, 17407.0% up from the prior year.
  • Net Margin was 3038.25% for Q1 2026 at Opus Genetics, down from 427.5% in the prior quarter.
  • Over five years, Net Margin peaked at 85.17% in Q4 2022 and troughed at 3038.25% in Q1 2026.
  • The 5-year median for Net Margin is 307.33% (2023), against an average of 515.75%.
  • Year-over-year, Net Margin skyrocketed 44083bps in 2025 and then plummeted -285074bps in 2026.
  • A 5-year view of Net Margin shows it stood at 85.17% in 2022, then tumbled by -433bps to 283.56% in 2023, then crashed by -188bps to 816.71% in 2024, then soared by 48bps to 427.5% in 2025, then crashed by -611bps to 3038.25% in 2026.
  • Per Business Quant, the three most recent readings for IRD's Net Margin are 3038.25% (Q1 2026), 427.5% (Q4 2025), and 566.87% (Q3 2025).